David Schiff
#148,808
Most Influential Person Now
Researcher
David Schiff's AcademicInfluence.com Rankings
David Schiffengineering Degrees
Engineering
#5931
World Rank
#7219
Historical Rank
Electrical Engineering
#1708
World Rank
#1806
Historical Rank
David Schiffcomputer-science Degrees
Computer Science
#7673
World Rank
#8077
Historical Rank
Computational Linguistics
#1577
World Rank
#1594
Historical Rank
Machine Learning
#2912
World Rank
#2948
Historical Rank
Artificial Intelligence
#3207
World Rank
#3254
Historical Rank
Download Badge
Engineering Computer Science
David Schiff's Degrees
- PhD Computer Science Stanford University
- Masters Electrical Engineering University of California, Berkeley
- Bachelors Computer Engineering University of California, Berkeley
Similar Degrees You Can Earn
Why Is David Schiff Influential?
(Suggest an Edit or Addition)David Schiff's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. (2009) (2276)
- A randomized trial of bevacizumab for newly diagnosed glioblastoma. (2014) (2145)
- NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. (2012) (650)
- MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. (2009) (608)
- Response assessment criteria for brain metastases: proposal from the RANO group. (2015) (553)
- Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. (2008) (472)
- Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. (2011) (458)
- Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. (2015) (441)
- Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08 (2006) (428)
- Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme (2005) (389)
- Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. (2020) (367)
- Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. (2007) (340)
- Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. (2013) (337)
- The continuing increase in the incidence of primary central nervous system non‐Hodgkin lymphoma (2002) (304)
- microRNA-34a is tumor suppressive in brain tumors and glioma stem cells (2010) (303)
- Risk of injury to cranial nerves after gamma knife radiosurgery for skull base meningiomas: experience in 88 patients. (1999) (298)
- Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. (2008) (274)
- Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. (2010) (265)
- Medical management of patients with brain tumors (2006) (236)
- Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. (2007) (224)
- A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. (2006) (223)
- Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. (2015) (201)
- Neurologic complications of chemotherapy agents (2007) (188)
- Malignant spinal-cord compression. (2005) (182)
- Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. (2014) (182)
- Primary central nervous system post‐transplantation lymphoproliferative disorder (2010) (163)
- Complications of therapy for venous thromboembolic disease in patients with brain tumors (1993) (160)
- Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults (2009) (158)
- Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas (2015) (157)
- Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. (2007) (157)
- Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. (2006) (155)
- A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. (2011) (154)
- Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. (2003) (153)
- Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the SPIne response assessment in Neuro-Oncology (SPINO) group. (2015) (151)
- Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study (2012) (150)
- A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) (2008) (148)
- Management of Low-Grade Glioma (2010) (148)
- International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. (2011) (145)
- Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression. (2010) (141)
- Oncogenic effects of miR-10b in glioblastoma stem cells (2013) (141)
- Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era (2013) (140)
- Low-grade gliomas: an update on pathology and therapy (2005) (139)
- Primary CNS lymphoma with intraocular involvement (2008) (137)
- Update on molecular findings, management and outcome in low-grade gliomas (2010) (129)
- Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51. (2011) (128)
- Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. (2007) (126)
- Phase I Study of GRN1005 in Recurrent Malignant Glioma (2013) (125)
- RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). (2013) (124)
- The Use of Magnetic Resonance Imaging to Noninvasively Detect Genetic Signatures in Oligodendroglioma (2008) (123)
- Part I: spinal-cord neoplasms-intradural neoplasms. (2007) (122)
- Advances in the genetics of glioblastoma: are we reaching critical mass? (2009) (120)
- Spinal cord compression. (2003) (119)
- Medical management of brain tumors and the sequelae of treatment. (2015) (119)
- Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. (2013) (115)
- Outcome in adult low-grade glioma (2007) (114)
- A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. (2015) (113)
- Neurological adverse effects caused by cytotoxic and targeted therapies (2009) (111)
- Venous thromboembolism in malignant gliomas (2010) (109)
- Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. (2013) (109)
- microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma. (2014) (109)
- Metastasis to nervous system: spinal epidural and intramedullary metastases (2005) (103)
- Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. (2008) (102)
- Outcome after spinal reirradiation for malignant epidural spinal cord compression (1995) (100)
- Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas. (2011) (100)
- Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. (2011) (99)
- XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. (2010) (98)
- Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs (2004) (98)
- Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. (2021) (97)
- Medical management of brain tumor patients. (2007) (96)
- Neuroimaging and treatment implications of patients with multiple epidural spinal metastases (1998) (95)
- Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. (2015) (94)
- MicroRNA-608 and MicroRNA-34a Regulate Chordoma Malignancy by Targeting EGFR, Bcl-xL and MET (2014) (94)
- Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. (1999) (93)
- PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations. (2008) (92)
- Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. (2010) (91)
- Surgery Insight: the role of surgery in the management of low-grade gliomas (2007) (90)
- Reversible posterior leukoencephalopathy syndrome in cancer (2008) (87)
- Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. (2017) (87)
- Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. (2008) (86)
- Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. (2018) (86)
- Cancer Neurology in Clinical Practice (2002) (85)
- Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. (2010) (81)
- Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas (2007) (80)
- Pharmacokinetic and Tumor Distribution Characteristics of Temsirolimus in Patients with Recurrent Malignant Glioma (2007) (78)
- Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma (2012) (76)
- Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02 (2018) (76)
- Targetable T-type Calcium Channels Drive Glioblastoma. (2017) (75)
- CNS Hodgkin lymphoma. (2008) (74)
- Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. (2018) (72)
- Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. (2011) (71)
- Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma (2008) (69)
- Gene therapy of malignant gliomas: a phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response. (2000) (69)
- A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients (2015) (68)
- Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. (2018) (68)
- Intramedullary spinal cord metastasis (ISCM) in renal cell carcinoma: a series of six cases. (2001) (68)
- Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma (2014) (68)
- Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB). (2010) (66)
- Neuropathological correlates of reversible posterior leukoencephalopathy (2005) (66)
- International study on low‐grade primary central nervous system lymphoma (2006) (66)
- Gene therapy of malignant gliomas: a pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response. (2001) (65)
- A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme (2007) (64)
- Thrombosis in Brain Tumors (2014) (63)
- Metastatic spinal cord compression by solid tumors. (2004) (62)
- Urgent considerations for the neuro-oncologic treatment of patients with gliomas during the COVID-19 pandemic (2020) (61)
- Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors. (2012) (61)
- Clinical implications of status epilepticus in patients with neoplasms. (2006) (60)
- Single brain metastasis (2001) (60)
- Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. (2005) (60)
- Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813 (2016) (58)
- Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. (2004) (58)
- Pneumocystis pneumonia in brain tumor patients: risk factors and clinical features (1996) (58)
- An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth. (2010) (57)
- Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. (1999) (57)
- A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme. (2009) (55)
- Recent Developments and Future Directions in Adult Lower-Grade Gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) Consensus. (2019) (55)
- Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy (2017) (53)
- The roles of viruses in brain tumor initiation and oncomodulation (2011) (53)
- Primary leptomeningeal lymphoma (2013) (51)
- Initial treatment patterns over time for anaplastic oligodendroglial tumors. (2012) (51)
- Primary Central Nervous System Lymphomas: A Validation Study of Array-Based Comparative Genomic Hybridization in Formalin-Fixed Paraffin-Embedded Tumor Specimens (2011) (51)
- Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in IDH-Mutant Lower Grade Gliomas (2019) (48)
- Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype (2019) (48)
- OPTIC NEUROPATHY IN PATIENTS WITH GLIOBLASTOMA RECEIVING BEVACIZUMAB (2009) (47)
- Metastatic Spinal Cord Compression In Patients With Colorectal Cancer (1999) (46)
- Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy (2009) (45)
- Treatment Considerations for MGMT-Unmethylated Glioblastoma (2014) (44)
- Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma (2019) (44)
- Neuroleukemiosis: Case report of leukemic nerve infiltration in acute lymphoblastic leukemia (2008) (44)
- A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE) (2019) (42)
- O6-benzylguanine suppression of O6-alkylguanine-DNA alkyltransferase in anaplastic gliomas. (2004) (42)
- A novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy. (2013) (42)
- microRNA-34 a is tumor suppressive in brain tumors and glioma stem cells (41)
- Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy (2017) (41)
- microRNA-34a promotes DNA damage and mitotic catastrophe (2013) (40)
- Pituitary carcinoma (2005) (39)
- Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas (2014) (39)
- A phase 1 and randomized, placebo‐controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872 (2019) (38)
- Part II: spinal-cord neoplasms--primary tumours of the bony spine and adjacent soft tissues. (2007) (38)
- Neurologic toxicities of cancer therapies (2006) (37)
- Spinal Cord Compression (2012) (37)
- Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma (2015) (37)
- Phase 2 and biomarker study of trebananib, an angiopoietin‐blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma (2018) (36)
- Long-term effects of cilengitide, a novel integrin inhibitor, in recurrent glioblastoma: A randomized phase IIa study. (2010) (35)
- Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas (2017) (34)
- Low-grade gliomas in older patients: a retrospective analysis of prognostic factors (2008) (34)
- Glioblastoma cell populations with distinct oncogenic programs release podoplanin as procoagulant extracellular vesicles. (2021) (33)
- Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572 (2018) (33)
- Hepatocyte Growth Factor Sensitizes Brain Tumors to c-MET Kinase Inhibition (2013) (32)
- Paraneoplastic recurrent multifocal encephalitis presenting with epilepsia partialis continua (2005) (32)
- Anti-GAD Antibody Positive Stiff-Limb Syndrome in Multiple Myeloma (2003) (32)
- CODEL: Phase III study of RT, RT + Temozolomide (TMZ), or TMZ for newly-diagnosed 1p/19q Codeleted Oligodendroglioma. Analysis from the initial study design. (2020) (31)
- Interim Analysis of a Phase I/II Study of Panobinostat in Combination with Bevacizumab for Recurrent Glioblastoma (P01.094) (2013) (31)
- Angiogenic inhibition in high-grade gliomas: past, present and future (2012) (31)
- Central nervous system toxicity from cancer therapies. (2006) (31)
- Gliomas arising in organ transplant recipients: An unrecognized complication of transplantation? (2001) (31)
- Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM). (2013) (30)
- Repeatability of 18F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma (2017) (29)
- Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high‐grade gliomas (2016) (28)
- SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. (2021) (28)
- Multimodal MR imaging model to predict tumor infiltration in patients with gliomas (2014) (28)
- Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma (2018) (28)
- Dasatinib in recurrent glioblastoma: failure as a teacher. (2015) (28)
- Monochorionic diamniotic minimally conjoined twins: a case report. (1990) (27)
- Phase IIa trial of cilengitide (EMD121974) single-agent therapy in patients (pts) with recurrent glioblastoma (GBM): EMD 121974-009 (2007) (27)
- Epidural spinal cord compression (2004) (27)
- Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma (2019) (25)
- Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors (2021) (25)
- LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma (2014) (25)
- Racial differences in primary central nervous system lymphoma incidence and survival rates. (2009) (25)
- Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline (2021) (24)
- Phase II study of AMG 102, a fully human neutralizing antibody against hepatocyte growth factor/scatter factor, in patients with recurrent glioblastoma multiforme (2008) (24)
- The Meckel syndrome in the Hutterites. (1980) (24)
- Neurologic emergencies in cancer patients. (1998) (23)
- It is time to include patients with brain tumors in phase I trials in oncology. (2011) (22)
- A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study. (2002) (22)
- Cooperation between c-Met and Focal Adhesion Kinase Family Members in Medulloblastoma and Implications for Therapy (2011) (21)
- Novel therapies for malignant gliomas. (2007) (21)
- Noncoding RNAs in Glioblastoma (2017) (21)
- Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma (2018) (21)
- Phase II trial of bevacizumab in patients with surgery and radiation refractory progressive meningioma. (2015) (20)
- FDG PET/MR Imaging Coregistration Helps Predict Survival in Patients with Glioblastoma and Radiologic Progression after Standard of Care Treatment. (2017) (20)
- Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines* (2019) (20)
- Redefining the Prevalence of Dural Involvement in Rosai-Dorfman Disease of the Central Nervous System. (2016) (20)
- Adrenal insufficiency secondary to glucocorticoid withdrawal in patients with brain tumor. (2007) (20)
- MR imaging characteristics of oligodendroglial tumors with assessment of 1p/19q deletion status (2010) (19)
- Individualized screening trial of innovative glioblastoma therapy (INSIGhT). (2017) (19)
- Culture conditions tailored to the cell of origin are critical for maintaining native properties and tumorigenicity of glioma cells. (2016) (19)
- Therapeutic Decision Making in Patients with Newly Diagnosed Low Grade Glioma (2014) (19)
- Disseminated strongyloidiasis complicating glioblastoma therapy: a case report (2009) (18)
- Molecular Subtype Classification in Lower-Grade Glioma with Accelerated DTI (2019) (18)
- Rare pathological variants and presentations of primary central nervous system lymphomas. (2006) (18)
- Checkpoint inhibitor failure in hypermutated and mismatch repair-mutated recurrent high-grade gliomas. (2019) (18)
- Neurological complications of new chemotherapy agents. (2018) (18)
- Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study (2015) (17)
- Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations. (2020) (17)
- Cintredekin besudotox in treatment of malignant glioma. (2008) (16)
- Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines. (2019) (16)
- Farnesylthiosalicylic acid induces caspase activation and apoptosis in glioblastoma cells (2006) (16)
- LTBK-08. TOCA 511 & TOCA FC VERSUS STANDARD OF CARE IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA (2019) (16)
- 11 – Extraaxial Brain Tumors (2010) (16)
- Effect of neoadjuvant temozolomide upon volume reduction and resection of diffuse low-grade glioma (2014) (16)
- Metastatic epidural spinal cord compression. (2010) (16)
- Cancer neurology in clinical practice : neurologic complications of cancer and its treatment (2008) (16)
- A model for the regulation of T-type Ca2+ channels in proliferation: roles in stem cells and cancer (2013) (16)
- Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. (2014) (16)
- The Ki-67 labeling index as a prognostic factor in Grade II oligoastrocytomas. (2005) (15)
- Osteoradionecrosis mimicking metastatic epidural spinal cord compression (2005) (15)
- Dephosphorylation of &bgr;-Arrestin 1 in Glioblastomas (2009) (15)
- Temozolomide and Radiation in Low-Grade and Anaplastic Gliomas: Temoradiation (2007) (15)
- Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression (2018) (15)
- Uncommon brain tumors. (1995) (15)
- Evolution of brain lesions in a patient with TREX1 cerebroretinal vasculopathy (2015) (14)
- Volumetric Analysis of IDH-Mutant Lower-Grade Glioma: A Natural History Study of Tumor Growth Rates Before and After Treatment. (2017) (14)
- Neurologic complications of solid tumors. (2003) (14)
- Glioblastoma genetics: in rapid flux. (2010) (14)
- Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397) (2016) (14)
- Automated apparent diffusion coefficient analysis for genotype prediction in lower grade glioma: association with the T2-FLAIR mismatch sign (2020) (14)
- Role of resection for newly diagnosed malignant gliomas (2003) (13)
- Risk of Venous Thromboembolism in Grade II–IV Gliomas as a Function of Molecular Subtype (2020) (13)
- Partial trisomy 12p due to t(12;21)pat translocation (2004) (13)
- Phase II study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma (rGBM). (2010) (13)
- Cintredekin besudotox in treatment of malignant glioma (2008) (13)
- Neuromuscular complications of cancer diagnosis and treatment. (2005) (13)
- Cerebral metastases—a therapeutic update (2006) (13)
- MRI and CT Identify Isocitrate Dehydrogenase (IDH)-Mutant Lower-Grade Gliomas Misclassified to 1p/19q Codeletion Status with Fluorescence in Situ Hybridization. (2019) (12)
- Supportive management of patients with brain tumors (2007) (12)
- Deceptively normal ventricular fluid in lymphomatous meningitis. (1993) (12)
- Bevacizumab in combination with irinotecan for patients with recurrent glioblastoma multiforme (2008) (12)
- ACTR-39. PAMIPARIB IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY (R/R) GLIOBLASTOMA (GBM); PHASE 1B/2 STUDY UPDATE (2019) (12)
- FDG PET/MRI Coregistration Helps Predict Response to Gamma Knife Radiosurgery in Patients With Brain Metastases. (2019) (12)
- Chemotherapy and cerebral metastases: misperception or reality? (2007) (12)
- Variable response of CNS hemangioblastomas to Pazopanib in a single patient with von Hippel-Lindau disease: Case report (2018) (12)
- Population description and clinical response assessment for spinal metastases: part 2 of the SPIne response assessment in Neuro-Oncology (SPINO) group report (2018) (11)
- Regression of an intramedullary spinal cord metastasis with a checkpoint inhibitor: a case report. (2017) (11)
- Management of neuro-oncologic emergencies. (2017) (11)
- Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era: Primary CNS PTLD (2013) (10)
- Preliminary results from a multicenter, phase II, randomized, noncomparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma (GBM). (2011) (10)
- ANG1005: Results of a phase I study in patients with recurrent malignant glioma. (2010) (10)
- Ongoing clinical trials. (2003) (9)
- Bone health in patients with brain tumors. (2007) (9)
- Phase 2 trial of SL-701 in relapsed/refractory (r/r) glioblastoma (GBM): Correlation of immune response with longer-term survival. (2018) (9)
- Dural and skull base metastases. (2007) (9)
- Results of NRG oncology/RTOG 9813: A phase III randomized study of radiation therapy (RT) and temozolomide (TMZ) versus RT and nitrosourea (NU) therapy for anaplastic astrocytoma (AA). (2015) (9)
- Much debated controversies of diffuse low-grade gliomas (2015) (9)
- Prognostic Value of Preoperative MRI Metrics for Diffuse Lower-Grade Glioma Molecular Subtypes (2020) (9)
- Preliminary results of the abemaciclib arm in the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A phase II platform trial using Bayesian adaptive randomization. (2021) (8)
- Subependymal seeding of low-grade oligodendroglial neoplasms: a case series (2012) (8)
- Epidural and intramedullary spinal metastasis: clinical features and role of fractionated radiotherapy. (2018) (8)
- Valproic acid as the AED of choice for patients with glioblastoma? (2011) (8)
- Fluid attenuation in non‐contrast‐enhancing tumor (nCET): an MRI Marker for Isocitrate Dehydrogenase (IDH) mutation in Glioblastoma (2021) (8)
- Gliomas following organ transplantation: analysis of the contents of a tumor registry. (2004) (8)
- Geographically Remote Cerebral Venous Sinus Thrombosis in Patients with Intracranial Tumors. (2017) (8)
- NCCTG N0872 (Alliance): A randomized placebo-controlled phase II trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma (GBM). (2015) (8)
- MNGO-04PHASE II TRIAL OF BEVACIZUMAB IN PATIENTS WITH SURGERY AND RADIATION REFRACTORY PROGRESSIVE MENINGIOMA (2015) (8)
- The p53-microRNA-34a axis regulates cellular entry receptors for tumor-associated human herpes viruses. (2013) (7)
- A phase I trial of LBH589 and bevacizumab for recurrent high-grade glioma (HGG). (2011) (7)
- Primary CNS lymphoma (2015) (7)
- Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. (2022) (7)
- Neurologic and Medical Management of Brain Tumors. (2018) (7)
- Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05) (2017) (7)
- Which donors with brain tumors are safe? (2004) (6)
- Fatal pulmonary embolism despite an inferior vena cava filter in glioblastoma multiforme (2005) (6)
- Donor transmission of primary brain tumors: A neurooncologic perspective (2004) (6)
- Features of diffuse gliomas that are misdiagnosed on initial neuroimaging: a case control study (2018) (6)
- Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations (2022) (6)
- Low-grade Gliomas (2015) (6)
- Eano-Euracan-Sno Guidelines on Circumscribed Astrocytic GLIOMAS, Glioneuronal and Neuronaltumors. (2022) (6)
- ACTR-30. PHASE 1B/2 STUDY TO ASSESS THE CLINICAL EFFECTS OF PAMIPARIB (BGB-290) IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY GLIOBLASTOMA (GBM) (2018) (6)
- Molecular profiling optimizes the treatment of low-grade glioma. (2016) (6)
- Improving Brain Tumor Research in Resource-Limited Countries: A Review of the Literature Focusing on West Africa (2015) (6)
- The siren song of bevacizumab: swan song or clarion call? (2018) (5)
- Primary Central Nervous System (PCNS) Post-Transplant Lymphoproliferative Disease (PTLD): An International Report of 65 Cases in the Modern Era (2011) (5)
- Neuro-oncology: Packer/Neuro-oncology (2012) (5)
- Neuro-oncology: Isocitrate dehydrogenase mutations in low-grade gliomas (2009) (5)
- Increased intratumoral infiltration in IDH wild-type lower-grade gliomas observed with diffusion tensor imaging (2019) (5)
- Reply to W. Wick et al (2010) (5)
- NCCTG N1174: Phase I/comparative randomized phase (Ph) II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma (GBM) (Alliance). (2017) (5)
- ATIM-11. PHASE 2 TRIAL OF SL-701, A NOVEL IMMUNOTHERAPY COMPRISED OF SYNTHETIC SHORT PEPTIDES AGAINST GBM TARGETS IL-13Rα2, EphA2, AND SURVIVIN, IN ADULTS WITH SECOND-LINE RECURRENT GBM: INTERIM RESULTS (2016) (5)
- The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment (2021) (5)
- Multi-modality Therapy Leads to Longer Survival in Primary Central Nervous System Lymphoma Patients (2002) (5)
- Improved molecular karyotyping in glioblastoma. (2018) (4)
- Case 5-1995: arteritis with multiple cerebral infarcts. (1995) (4)
- Management of Venous Thromboembolism in High-Grade Glioma: Does Low Molecular Weight Heparin Increase Intracranial Bleeding Risk? (2021) (4)
- Neuro-oncology: Five new things. (2013) (4)
- Brain tumors in adults (2007) (4)
- Neurological and Medical Complications in Brain Tumor Patients (2020) (4)
- Phase II study of antiangiogenic (metronomic) chemotherapy for recurrent malignant gliomas. (2006) (4)
- Predictors of early, recurrent, and intractable seizures in low-grade glioma. (2020) (4)
- NEURO/MEDICAL ONCOLOGY (2013) (4)
- NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: A North Central Cancer Treatment Group study. (2011) (4)
- Incidence, risk factors and management of venous thromboembolism in patients with primary CNS lymphoma (2021) (4)
- Living in a material world: tumor-treating fields at the top of the charts. (2016) (4)
- Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM). (2018) (4)
- Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline (2022) (4)
- Intracranial germ cell tumors in Adolescents and Young Adults: European and North American consensus review, current management and future development. (2021) (4)
- Evaluating the benefit of adaptive randomization in the CC-115 arm of the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A phase II randomized Bayesian adaptive platform trial in newly diagnosed MGMT unmethylated glioblastoma. (2021) (4)
- Oligodendroglioma confers higher risk of radiation necrosis (2019) (3)
- A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma (2022) (3)
- Low-grade Gliomas (2017) (3)
- Chapter 170 – Uncommon Brain Tumors, Skull Base Tumors, and Intracranial Cysts (2003) (3)
- Unmet needs in the treatment of glioblastoma (2009) (3)
- NCCTG (Alliance) N0572: A phase II trial of sorafenib and temsirolimus in recurrent glioblastoma (GBM) patients who progress following prior RT/temozolomide (TMZ) and VEGF inhibitors (VEGFi). (2013) (3)
- Current Considerations in the Treatment of Grade 3 Gliomas (2022) (3)
- Combined immunochemotherapy with reduced dose whole brain radiotherapy (WBRT) for newly diagnosed patients with primary CNS lymphoma (PCNSL). (2004) (3)
- POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM (2004) (3)
- Multimodality Therapy of Patients with Refractory Meningiomas (2019) (3)
- Defining optimal initial therapy for primary CNS lymphoma. (2016) (3)
- Dramatic response to chemotherapy in oligodendroglial gliomatosis cerebri (2003) (3)
- CTNI-29. CODEL: PHASE III TRIAL OF RT ALONE, RT PLUS TMZ, OR TMZ ALONE FOR NEWLY-DIAGNOSED, 1p/19q CODELETED ANAPLASTIC OLIGODENDROGLIOMA. ANALYSIS FROM THE INITIAL STUDY DESIGN. (NCCTG N0577, ALLIANCE) (2020) (3)
- Cancer Neurology in Clinical Practice (2018) (3)
- Primary intraocular lymphoma (PIOL): An International Primary CNS Lymphoma Collaborative group report. (2006) (3)
- Neurologic Complications of Head and Neck Cancer (2003) (3)
- Panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. (2014) (3)
- OS5.8 Intravascular lymphoma affecting the central nervous system: features and outcomes in a case series of the Primary CNS Lymphoma Collaborative Group (IPCG) (2016) (3)
- Benefit with adjuvant chemotherapy in anaplastic astrocytoma (2017) (3)
- A phase II study of prolonged daily temozolomide for low-grade glioma (2005) (3)
- A 21-year-old woman with multiple cancers and a new brain lesion (2012) (2)
- Imaging of Epidural Spinal Cord Compression (2016) (2)
- PCV in low-grade gliomas: benefit from old drugs in an evolving disease entity. (2016) (2)
- Kyphoplasty in cancer: an encouraging step. (2011) (2)
- CTNI-18. PHASE I AND PRELIMINARY PHASE 0 RESULTS OF ABTC 1801: A MULTI-ARM CLINICAL TRIAL OF THE PARP INHIBITOR PAMIPARIB (BGB290) WITH VERY LOW DOSE METRONOMIC TEMOZOLOMIDE IN RECURRENT IDH MUTANT GLIOMAS (2021) (2)
- Low-grade gliomas. (2011) (2)
- CTNI-11. CC-115 IN NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II RANDOMIZED BAYESIAN ADAPTIVE PLATFORM TRIAL (2020) (2)
- Neurologic Complications of Genitourinary Malignancies (2003) (2)
- Feasibility and conduct of INSIGhT, a platform trial of patients with glioblastoma using Bayesian adaptive randomization. (2022) (2)
- Abstract B49: GRN1005 phase I studies: Final results. (2011) (2)
- A randomized, double‑blind, controlled phase IIb study of the safety and efficacy of ICT‑107 in newly diagnosed patients with glioblastoma multiforme following resection and chemoradiation. (2012) (2)
- An alternative to radiotherapy in consolidation of brain lymphoma. (2017) (2)
- Phase I study of vandetanib with radiation therapy and temozolomide for newly diagnosed glioblastoma. (2016) (2)
- NCCTG N057K phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: A North Central Cancer Treatment Group trial. (2012) (2)
- MEDICAL RADIATION THERAPIES (2013) (2)
- Consolidation reduced dose whole brain radiotherapy (rdWBRT) following methotrexate, rituximab, procarbazine, vincristine, cytarabine (R-MPV-A) for newly diagnosed primary CNS lymphoma (PCNSL): Final results and long-term outcome. (2012) (2)
- Cancer and the Nervous System (2008) (2)
- Isolated Brain Parenchyma Relapse of Non-Hodgkin’s Lymphoma (NHL): A Descriptive Analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG). (2006) (2)
- Genome-Wide Analysis Uncovers Recurrent Alterations in Primary Central Nervous System Lymphomas (2012) (2)
- Quantifying the burden of primary central nervous system malignancy. (2016) (2)
- The blood-brain barrier limits the therapeutic efficacy of antibody drug conjugates in glioblastoma. (2021) (2)
- CTNI-12. PRELIMINARY RESULTS OF THE ABEMACICLIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION (2020) (2)
- EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults (2021) (2)
- Phase II trial of triple-receptor tyrosine kinase receptor inhibitor nintedanib (BIBF 1120) in recurrent high-grade gliomas. (2013) (2)
- Neurologic Complications of Genitourinary Cancer (2008) (2)
- The first reported localisation and resection of a brain tumour. (2010) (2)
- Primary Central Nervous System Post-Transplatation Lymphoproliferative Disorder (2010) (1)
- How can we develop therapies for glioblastoma more efficiently? Randomized versus single-arm studies. (2017) (1)
- Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance) (2022) (1)
- CTNI-38. PAMIPARIB IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED (ND) OR RECURRENT/REFRACTORY (R/R) GLIOBLASTOMA (GBM); PHASE 1B/2 STUDY UPDATE (2020) (1)
- GENOME-WIDE ANALYSIS UNCOVERS RECURRENT ALTERATIONS IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS (PCNSL) (2014) (1)
- Neurological complications of solid tumors. (2012) (1)
- Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas: Final results. (2014) (1)
- Reply to Primary central nervous system post‐transplantation lymphoproliferative disorder (2010) (1)
- Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline (2021) (1)
- Headache as Complication of Cancer (2018) (1)
- Lower-grade gliomas: the wrong target for bevacizumab. (2018) (1)
- OMICS AND PROGNSTIC MARKERS (2013) (1)
- ATIM-06. PHASE 2 TRIAL OF SL-701 + BEVACIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED GLIOBLASTOMA (GBM) MEETS PRIMARY ENDPOINT OF OS-12, WITH PRELIMINARY CORRELATION BETWEEN LONG-TERM SURVIVAL AND TARGET-SPECIFIC CD8+ T CELL IMMUNE RESPONSE (2018) (1)
- CTNI-05. PRELIMINARY RESULTS OF THE NERATINIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION (2021) (1)
- Status Epilepticus in Patients With CNS Metastases—Reply (2007) (1)
- Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours (2019) (1)
- Safety Profile of Maintenance Obinutuzumab in Patients with Primary CNS Lymphoma in Complete Response (2020) (1)
- Cooperation between the SF/HGF:c-Met pathway and c-Myc in human medulloblastoma malignancy (2006) (1)
- Altered consciousness associated with brain neoplasms. (2008) (1)
- Kinetic and Wavelet Analysis of Dynamic FDG PET Data in Human Glioblastoma (2017) (1)
- The Genomic Landscape Of Primary Central Nervous System Lymphomas (2013) (1)
- Combination immunochemotherapy followed by reduced dose (rd) whole brain radiation therapy (WBRT) in an expanded cohort of patients with newly diagnosed primary central nervous system lymphoma (PCNSL). (2016) (1)
- Encephalomyeloradiculoneuropathy Revealing a Rare Case of Intravascular Large B-Cell Lymphoma (2021) (1)
- METASTATIC SPINAL CORD DISEASE (2005) (1)
- Abstract 345: PTEN tumor suppressive effects in glioblastoma are partly mediated by MET downregulation via a p53-miR-34a axis (2017) (1)
- Reply: Liver grafts from donors with central nervous system tumors: A single‐center perspective (2010) (1)
- Medical and Neuro-Oncology (2010) (1)
- was pro-Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study 1 (2003) (0)
- CLRM-07. INCREASING EFFICIENCY IN EARLY PHASE MULTICENTER IMAGING BIOMARKER TRIALS: EMERGING STRATEGIES FROM THE GABLE (GLIOBLASTOMA ACCELERATED BIOMARKER LEARNING ENVIRONMENT) TRIAL (2021) (0)
- Correction to: Neurological and Medical Complications in Brain Tumor Patients (2020) (0)
- Are patients with oligodendroglioma at higher risk for radiation neurotoxicity? (2019) (0)
- Abstract 3147: Comprehensive characterization of the role of T-type calcium channels in glioblastoma (2017) (0)
- Abstract 102: Overcoming MET inhibitor resistance in GBM therapy (2017) (0)
- Phase II Study of Rituximab Given in Conjunction with Standard Chemotherapy in Primary Central Nervous System Lymphoma (PCNSL)[E1F05] (2015) (0)
- Case of the month: Leukemic nerve infiltration (2009) (0)
- Low grade gliomas of the elderly: Characterizing a rare entity (2006) (0)
- Status epilepticus in patients with CNS metastases. Authors' reply (2007) (0)
- ATPS-01INHIBITION OF T-TYPE CALCIUM CHANNELS SENSITIZES GLIOBLASTOMA STEM CELLS TO CHEMOTHERAPY (2015) (0)
- Epidural Spinal Cord Compression in Adult Neoplasms (2016) (0)
- 421TiPPhase 1b/2 study to assess the clinical effects of BGB-290 in combination with radiation therapy (RT) and/or temozolomide (TMZ) in patients with first-line or recurrent/refractory glioblastoma (2017) (0)
- Comprar Brain Tumors in Adults, An Issue of Neurologic Clinics | Patrick Wen | 9781416051954 | Saunders (2007) (0)
- CTIM-11. PHASE 2 STUDY OF SL-701, A NOVEL IMMUNOTHERAPY, IN ADULTS WITH RECURRENT GBM: A HIGH PARAMETER FLOW CYTOMETRY ANALYSIS OF CD8+ T CELLS AND POTENTIAL IMPLICATIONS FOR PATIENT ENRICHMENT STRATEGIES (2021) (0)
- Focal Neuronal Gigantism: A Rare Complication of Therapeutic Radiation (2009) (0)
- Neurological Complications of Chemotherapy (2019) (0)
- Correction to: Incidence, risk factors and management of venous thromboembolism in patients with primary CNS lymphoma (2021) (0)
- Correction to: Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma (2018) (0)
- CTIM-29. PHASE 2 STUDY OF A NOVEL IMMUNOTHERAPY SL-701 IN ADULTS WITH RECURRENT GBM: IDENTIFICATION OF TREATMENT-INDUCED CD8+CD107A+ CD57+ PD-1- MEMORY T-CELLS THAT ARE ASSOCIATED WITH INCREASED SURVIVAL (2022) (0)
- Therapeutic Discovery Cooperation between c-Met and Focal Adhesion Kinase Family Members in Medulloblastoma and Implications for Therapy (2012) (0)
- Abstract 331: A comprehensive high-resolution genomic analysis of primary central nervous system lymphomas (PCNSL) shows a highly complex karyotype characterized by abnormalities affecting multiple genes involved in critical pathways associated with lymphocyte maturation and survival (2010) (0)
- P14.23 Risk of venous thromboembolism (VTE) in grade II-IV gliomas as a function of molecular subtype (2019) (0)
- Faculty Opinions recommendation of Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. (2009) (0)
- Update on Management of Brain Metastases from Melanoma (2004) (0)
- Highlights from the literature (2021) (0)
- CTNI-40. EVALUATING FEASIBILITY AND EFFICIENCY OF PHASE II ADAPTIVE PLATFORM TRIAL DESIGNS BASED ON THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGhT) EXPERIENCE (2021) (0)
- 16 – Clinical trials and chemotherapy (2012) (0)
- ARTE and craft of bevacizumab in elderly patients with glioblastoma. (2018) (0)
- Quality of life in patients with pure and mixed anaplastic oligodendroglioma treated with dose-intense temozolomide: A phase II multicenter study. (2010) (0)
- Timed-sequential therapy with mibefradil and temozolomide in patients with recurrent high-grade gliomas: A phase I Adult Brain Tumor Consortium study. (2015) (0)
- NIMG-81. EFFECT OF RE-TREATMENT WITH TEMOZOLOMIDE IN GRADE 2/3 IDH MUTANT GLIOMAS AT FIRST PROGRESSION (2022) (0)
- Abstract B160: ANG1005: New EPiC compound for the treatment of recurrent malignant glioma (2009) (0)
- MTR-13EVALUATION OF p75 EXPRESSION AND PATTERNS OF RECURRENCE IN PATIENTS WITH MALIGNANT GLIOMAS TREATED WITH BEVACIZUMAB (2015) (0)
- Temozolomide, an Oral Alkylating Agent, Effective in Treating Glioblastoma (2005) (0)
- AT-36PANOBINOSTAT IN COMBINATION WITH BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA AND ANAPLASTIC GLIOMA (2014) (0)
- Basic principles of brain tumor chemotherapy (2019) (0)
- QOL-09. NAVIGATING DISABILITY INSURANCE FOR PATIENTS DIAGNOSED WITH LOW-GRADE GLIOMA (2022) (0)
- Response to C. Massard et al (2012) (0)
- Comprar Neuro-Oncology | Roger J. Packer | 9780470655757 | Wiley (2012) (0)
- Comment: Can APOE genotyping predict cognitive damage from brain tumor therapy? (2014) (0)
- Comprar Neurologic Complications Of Cancer Therapy | Patrick Wen | 9781936287079 | Demos Medical Publishing (2011) (0)
- Development and validation of a liquid chromatography coupled with tandem mass spectrometry method for determining total and unbound pamiparib in human plasma and brain tumors. (2022) (0)
- Hepatotoxicity from High-Dose Methotrexate in Primary Central Nervous System Lymphoma (2023) (0)
- Comprar Cancer Neurology in Clinical Practice · Neurologic Complications of Cancer and Its Treatment | Wen, Patrick Yung Chih | 9781588299833 | Springer (2008) (0)
- Comment: Neoplastic meningitis—Improving accuracy of a sometimes elusive diagnosis (2013) (0)
- Abstract 1252: Cooperation between c-Met and focal adhesion kinase pathways in medulloblastoma and implications for therapy (2012) (0)
- RARE-23TWO CASES OF RARE INTRASPINAL POORLY DIFFERENTIATED NEUROENDOCRINE TUMOR WITH EXCELLENT RESPONSES TO RADIATION THERAPY. (2015) (0)
- Epilepsy and Anticonvulsant Therapy in Brain Tumor Patients (2019) (0)
- Brain and Spinal Cord (2017) (0)
- NTCT-13VAGOGLOSSOPHARYNGEAL NEURALGIA PRESENTING AS FREQUENT SEIZURE-LIKE SPELLS IN A PATIENT WITH HEAD AND NECK CANCER TREATED WITH HIGH CUMULATIVE RADIATION DOSE (2015) (0)
- Abstract A73: Racial/ethnic differences in primary central nervous system lymphoma: A SEER-based estimate of incidence and survival rates among American blacks, American whites, Asian/Pacific Islanders and American Indians/Alaskan natives (2009) (0)
- A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma (2011) (0)
- SBRT and spinal metastasis: finding its niche. (2012) (0)
- NIMG-35RESULTS OF EXPLORATORY 18F-FLT PET IMAGING IN TEN RECURRENT HIGH-GRADE GLIOMA PATIENTS TREATED WITH THE SELECTIVE T-TYPE CALCIUM CHANNEL BLOCKER MIBEFRADIL FOLLOWED BY TEMOZOLOMIDE (ABTC TRIAL 1101) (2015) (0)
- Brain tumor patients with uncertain metastatic potential as organ donors in infancy and childhood. (2010) (0)
- Faculty Opinions recommendation of Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. (2010) (0)
- Spinal Metastasis as Complication of Systemic Cancers (2018) (0)
- Neuro-oNcology To determine racial and ethnic differences in incidence and survival in patients with primary central nervous system lymphoma ( PCNSL ) (2009) (0)
- PC3 - 151 Toca 5: A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined with Toca FC versus Standard of Care in Patients Undergoing Planned Resection for Recurrent Glioblastoma (GBM) or Anaplastic Astrocytoma (AA) (NCT02414165) (2016) (0)
- Brain Tumor in the Elderly (2010) (0)
- Abstract 1821: Hepatocyte growth factor sensitizes brain tumor cells and xenografts to c-Met kinase inhibition (2012) (0)
- Specific targeting of pediatric brainstem gliomas with histone demethylase inhibitors (2015) (0)
- EP1207: HEPATOTOXICITY FROM HIGH-DOSE METHOTREXATE IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (2022) (0)
- Vascular complications in patients with brain tumors (2022) (0)
- Spinal Epidural Metastases (2010) (0)
- Book Review Parkinson's Disease: Anatomy, pathology, and therapy (Advances in Neurology. Vol. 53.) Edited by Max B. Streifler, Amos D. Korczyn, Eldad Melamed, and Moussa B.H. Youdim. 596 pp., illustrated. New York, Raven Press, 1990. $125. (1991) (0)
- ALLELE: A consortium for prospective genomics and functional diagnostics to guide patient care and trial analysis in newly-diagnosed glioblastoma. (2018) (0)
- Abstract 126: Characterization of microRNA-10b in human glioblastoma (2011) (0)
- Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas. (2022) (0)
- Abstract 1909: Identification and characterization of microRNA-134 as a novel receptor tyrosine kinase-regulated tumor suppressive hub in glioblastoma (2014) (0)
- Preliminary Data from a Multicenter, Phase II, Randomized, Non-Comparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly-Diagnosed Glioblastoma (GBM) (S45.006) (2012) (0)
- Metastatic Disease and the Nervous System (2021) (0)
- Validating RNAseq-signatures of vorinostat (VOR) sensitivity and resistance in patients with newly diagnosed glioblastoma (GBM) treated with VOR, temozolomide and radiation therapy in Alliance N0874/ABTC-0902. (2016) (0)
- Sequential therapy with the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas: An Adult Brain Tumor Consortium phase I study (ABTC1101). (2013) (0)
- ATIM-05. A PHASE I STUDY TARGETING NEWLY DIAGNOSED GLIOBLASTOMA WITH ANTI-CD3 × ANTI-EGFR BISPECIFIC ANTIBODY ARMED T CELLS (EGFR BATS) IN COMBINATION WITH RADIATION AND TEMOZOLOMIDE (2019) (0)
- Central Nervous System Complications Among Oncology Patients. (2021) (0)
- Avastin and Malignant Gliomas (2010) (0)
- Abstract 5222: microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma (2014) (0)
- RARE-01. INTRAVASCULAR LYMPHOMA (IVL). A SINGLE INSTITUTION STUDY FROM THE MODERN NEURO-IMAGING ERA (2016) (0)
- Acetazolamide for treatment of drop attacks due to Symptomatic Plateau Waves: A case report (P4.211) (2015) (0)
- Epidemiology, biology, and management of venous thromboembolism in gliomas: An interdisciplinary review. (2023) (0)
- COVD-31. THE STATE OF NEURO-ONCOLOGY DURING THE COVID-19 PANDEMIC: A WORLDWIDE ASSESSMENT (2020) (0)
- 765 A Phase I Study of an IL-4-HSV-tk Gene-modified Autologous Glioma Vaccine: Technical Challenges and Promising Initial Results (2001) (0)
- Epidural metastasis and spinal cord compression (2016) (0)
- Abstract 2067: Effects of microRNA-34a on brain tumor cells and glioblastoma stem cells (2010) (0)
- CNS Post-Transplant Lymphoproliferative Disorder (2003) (0)
- Highlights from the literature (2013) (0)
- Male gender is associated with seizure risk in low-grade glioma (LGG) patients. (2019) (0)
- Chapter 154 – Classification, Epidemiology, and Etiology of Brain Tumors (2003) (0)
- Characterization of the Copy-Number Changes In Primary CNS Lymphomas (PCNSL) by High-Resolution Array-Based Comparative Genomic Hybridization (2010) (0)
- 18. ALLELE: A consortium for prospective genomics and functional diagnostics to guide patient care and trial analysis in newly-diagnosed glioblastoma (2018) (0)
- Abstract 5081: Comprehensive genomic analysis of primary CNS lymphomas (PCNSL) identifies multiple dysregulated genes involved in immune response, regulation of apoptosis, lymphocyte maturation and activation (2012) (0)
- Navigating disability insurance in the American healthcare system for the low-grade glioma patient. (2022) (0)
- Prevention of malignant spinal-cord compression – Authors' reply (2005) (0)
- CLIN-NEURO/MEDICAL ONCOLOGY (2012) (0)
- F1000Prime recommendation of High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. (2011) (0)
- A new class of radiosensitizers for glioblastoma (2021) (0)
- CHAPTER 52 – Imaging of Epidural Spinal Cord Compression (2008) (0)
- INNV-13. ALLELE: A CONSORTIUM FOR PROSPECTIVE GENOMICS AND FUNCTIONAL DIAGNOSTICS TO GUIDE PATIENT CARE AND TRIAL ANALYSIS IN NEWLY-DIAGNOSED GLIOBLASTOMA (2018) (0)
- Figure 1, [miRNA biogenesis and functions. Black...]. (2017) (0)
- Response to Weltman and Fleury Malheiros, re Lassman et al. (2012) (0)
- NCMP-31. RISK OF INTRACRANIAL HEMORRHAGE (ICH) IN PATIENTS WITH HIGH-GRADE GLIOMA (HGG) ON THERAPEUTIC LOW MOLECULAR WEIGHT HEPARIN (LMWH) (2018) (0)
- Keep up with Critical Fields (2012) (0)
- Neurologic Complications of Cancer Therapy (2011) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With David Schiff?
David Schiff is affiliated with the following schools:
